Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Application of Immune Checkpoint Inhibitors in EGFR Mutant  Advanced Non-small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Sept 2022

Zheng Yujun, Jiang Wei, Li Jing, Dai Lulu, Chen Dongyan, Li Yanjun, Huang Lei, Wang Mingji

Abstract excerpt

In recent years, immune checkpoint inhibitors (ICIs) have greatly improved the survival rate of non-small cell lung cancer (NSCLC) patients without driver mutation. Compared with wild-type tumors, tumors with epidermal growth factor receptor (EGFR) mutations have greater heterogeneity in immune microenvironment characteristics such as programmed cell death ligand 1 (PD-L1) and tumor mutational burden (TMB)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Ligands

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36172732
DOI: 10.3779/j.issn.1009-3419.2022.102.32
PMCID: PMC9549429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].PMID 36172732Read ↗

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity Read ↗

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].Semantic proximity Read ↗

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read ↗

[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].Semantic proximity Read ↗

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Semantic proximity Read ↗

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read ↗

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read ↗

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.Semantic proximity Read ↗

[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].Semantic proximity Read ↗

The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.